WO2007012906A1 - New 1 , 2 -diaryl pyrazoles useful as analgetic and anti-inflammatory agents - Google Patents
New 1 , 2 -diaryl pyrazoles useful as analgetic and anti-inflammatory agents Download PDFInfo
- Publication number
- WO2007012906A1 WO2007012906A1 PCT/HU2006/000063 HU2006000063W WO2007012906A1 WO 2007012906 A1 WO2007012906 A1 WO 2007012906A1 HU 2006000063 W HU2006000063 W HU 2006000063W WO 2007012906 A1 WO2007012906 A1 WO 2007012906A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- group
- pharmaceutically acceptable
- inflammation
- Prior art date
Links
- 230000000202 analgesic effect Effects 0.000 title description 8
- 239000000730 antalgic agent Substances 0.000 title description 5
- 239000002260 anti-inflammatory agent Substances 0.000 title description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 79
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 206010061218 Inflammation Diseases 0.000 claims abstract description 18
- 230000004054 inflammatory process Effects 0.000 claims abstract description 18
- 239000012453 solvate Substances 0.000 claims abstract description 17
- 150000004677 hydrates Chemical class 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 239000003513 alkali Chemical group 0.000 claims abstract description 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 5
- 125000002252 acyl group Chemical group 0.000 claims abstract description 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims abstract description 5
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 208000035475 disorder Diseases 0.000 claims abstract description 5
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 5
- 125000001118 alkylidene group Chemical group 0.000 claims abstract description 4
- 230000008569 process Effects 0.000 claims abstract description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 239000012442 inert solvent Substances 0.000 claims description 9
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 8
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 5
- IOMZCWUHFGMSEJ-UHFFFAOYSA-N 4-(azaniumylamino)benzenesulfonate Chemical compound NNC1=CC=C(S(O)(=O)=O)C=C1 IOMZCWUHFGMSEJ-UHFFFAOYSA-N 0.000 claims description 3
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 claims description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 abstract description 8
- 230000036407 pain Effects 0.000 abstract description 8
- 208000005171 Dysmenorrhea Diseases 0.000 abstract description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract description 2
- 208000038016 acute inflammation Diseases 0.000 abstract description 2
- 230000006022 acute inflammation Effects 0.000 abstract description 2
- 208000037976 chronic inflammation Diseases 0.000 abstract description 2
- 230000006020 chronic inflammation Effects 0.000 abstract description 2
- 208000004550 Postoperative Pain Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 23
- 229960000590 celecoxib Drugs 0.000 description 22
- 235000010418 carrageenan Nutrition 0.000 description 20
- 239000000679 carrageenan Substances 0.000 description 20
- 229920001525 carrageenan Polymers 0.000 description 20
- 229940113118 carrageenan Drugs 0.000 description 20
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 20
- 239000000725 suspension Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 210000002683 foot Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 208000000114 Pain Threshold Diseases 0.000 description 9
- 230000037040 pain threshold Effects 0.000 description 9
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 8
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 208000004454 Hyperalgesia Diseases 0.000 description 6
- 208000035154 Hyperesthesia Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 6
- 210000000548 hind-foot Anatomy 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- PUSLMFHAVRXHIB-UHFFFAOYSA-N 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonyl chloride Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(Cl)(=O)=O)C=C1 PUSLMFHAVRXHIB-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000003628 erosive effect Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- WIENENPMVANVOX-UHFFFAOYSA-N 2-[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]sulfonylamino]oxypropanoic acid Chemical compound C1=CC(S(=O)(=O)NOC(C)C(O)=O)=CC=C1N1C(C=2C=CC(C)=CC=2)=CC(C(F)(F)F)=N1 WIENENPMVANVOX-UHFFFAOYSA-N 0.000 description 2
- YJZMNUBOOFPLKI-UHFFFAOYSA-N 3-[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]sulfonylamino]oxypropanoic acid Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(=O)(=O)NOCCC(O)=O)C=C1 YJZMNUBOOFPLKI-UHFFFAOYSA-N 0.000 description 2
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 2
- QGIWLVKNOVQTKV-UHFFFAOYSA-N 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonic acid Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(O)(=O)=O)C=C1 QGIWLVKNOVQTKV-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000003293 cardioprotective effect Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- RHQSXEALXQMPAV-UHFFFAOYSA-N ethyl 2-[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]sulfonylamino]oxypropanoate Chemical compound C1=CC(S(=O)(=O)NOC(C)C(=O)OCC)=CC=C1N1C(C=2C=CC(C)=CC=2)=CC(C(F)(F)F)=N1 RHQSXEALXQMPAV-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 2
- 229960004027 molsidomine Drugs 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- KRIOVPPHQSLHCZ-UHFFFAOYSA-N propiophenone Chemical compound CCC(=O)C1=CC=CC=C1 KRIOVPPHQSLHCZ-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960000371 rofecoxib Drugs 0.000 description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 1
- KWGRBVOPPLSCSI-PSASIEDQSA-N (1s,2r)-2-(methylamino)-1-phenylpropan-1-ol Chemical compound CN[C@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-PSASIEDQSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CWEWBCLCRPGTIO-UHFFFAOYSA-N 2-aminooxypropanoic acid;hydrochloride Chemical compound Cl.NOC(C)C(O)=O CWEWBCLCRPGTIO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 0 Cc(cc1)ccc1-c1cc(C(F)(F)F)n[n]1-c(cc1)ccc1S(NOC*)(=O)=O Chemical compound Cc(cc1)ccc1-c1cc(C(F)(F)F)n[n]1-c(cc1)ccc1S(NOC*)(=O)=O 0.000 description 1
- 238000003512 Claisen condensation reaction Methods 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 108700043492 SprD Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
- FRFOTFXCOZJZQT-UHFFFAOYSA-N [[4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]sulfonylamino] benzoate Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(=O)(=O)NOC(=O)C=2C=CC=CC=2)C=C1 FRFOTFXCOZJZQT-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- OUKMIBMGMKGMIT-UHFFFAOYSA-N n-hydroxy-4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(=O)(=O)NO)C=C1 OUKMIBMGMKGMIT-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the invention relates to new compounds of formula (I) and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, which are useful in treating pain originated from acute and chronic inflammation as well as surgical action and dysmenorrhea. Furthermore the invention relates to the synthesis of compounds of formula (I) and the pharmaceutical compositions containing them.
- Celecoxib is described in the European patent EP 731795. Certain problems arose during the use of it. On the one hand celecoxib is not effective in all cases of patients therefore the research for more effective analogous drugs have started. On the other hand it is desirable to reduce the gastrointestinal side-effects. It is known from the literature that the research was focused on increasing the selective inhibition of COX-2 enzyme in order to decrease the gastrointestinal side-effects. This raises the question of cardiovascular side-effects, as according to the previous observations increasing the selectivity of COX-2 inhibition resulted in increasing cardiovascular side-effects.
- celecoxib derivatives are more effective analgetic and anti-inflammatory agents than celecoxib, furthermore they do not have in vitro COX-I and COX-2 inhibitory activity and their gastrointestinal side-effect profile is essentially more favorable, as well as they have cardioprotective activity.
- the present invention relates to new compounds of formula (I),
- R 1 is hydrogen atom, C 1 -C 5 acyl group, benzoyl group or R 2 -COOR 3 group
- Y is hydrogen atom or alkali ion
- R 2 is C 1 -C 4 straight or branched alkylidene group
- R 3 is hydrogen atom, C 1 -C 4 alkyl group or alkali ion, and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof.
- the invention also relates to the process of their synthesis as well as the pharmaceutical composition containing the same and the use for treatment of pain, inflammation and disorders associated with inflammation.
- the present invention relates to new compounds of formula (I),
- R 1 is hydrogen atom, C 1 -C 5 acyl group, benzoyl group or R 2 -COOR 3 group
- Y is hydrogen atom or alkali ion
- R 2 is C 1 -C 4 straight or branched alkylidene group
- R 3 is hydrogen atom, C 1 -C 4 alkyl group or alkali ion, and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof.
- the alkali ion is preferably sodium.
- the invention also relates to solvates and hydrates of compounds of formula (I). hi those cases when compounds of formula (I) have chiral centre both stereoisomers and the racemic mixture of them are subject of the invention.
- the invention also relates to the process of the synthesis of compounds of formula (I) and the chemical and pharmaceutical manufacture of pharmaceutical compositions containing the same, as well as the methods of treatment and/or prevention with these compounds, which means administering to a mammal - including human - to be treated effective amount/amounts of compounds of formula (I) of the present invention as such or as medicament.
- Claisen reaction of the commercially available p-methyl-acetophenone and trifluoroacetic acid ethyl ester gave 4,4,4-trifluoro-l-(4-methylphenyl)-butane-l,3-dione in good yield.
- Those compounds of formula (I), wherein the meaning of R 3 is hydrogen atom can be transformed into alkali salts with alkali hydroxide solution, preferably with two equivalent of sodium hydroxide.
- the formed disodium salt can contain hydrate as solvate, preferably monohydrate. If compound of formula (II) is reacted with O-acylated hydroxylamine in an inert solvent, preferably in dioxane, those compounds of formula (I) are formed in high yield, wherein the meaning OfR 1 is C 1 -C 5 acyl group or benzoyl group.
- the invention also relates to pharmaceutical compositions containing compounds of formula (I) as an active ingredient.
- Compounds of formula (I) can be used in treating of inflammation and disorders associated with inflammation, for example as an analgesic agent in treatment of pain and headache.
- Compounds of formula (I) and/or stereoisomers and/or diastereomers can be used as such and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof as medicament, usually as a standard composition.
- the present invention also relates to pharmaceutical compositions containing a new compound of formula (I) and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof as well as one or more pharmaceutically acceptable adjuvant and auxiliary material.
- Compounds of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof may be administered by any convenient method, for example by oral, parenteral buccal, sublingual, nasal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly.
- Pharmaceutical compositions containing compounds of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof when given orally can be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and chewable tablets..
- Liquid formulations of compounds of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof generally consist of a suspension or solution of a compound of formula (I) in an appropriate liquid carrier(s), for example an aqueous solvent, such as water, ethanol or glycerine or a non-aqueous solvent, such as polyethylene glycol or an oil.
- the pharmaceutical composition can also contain a suspending agent, preservative, flavoring and coloring agents.
- a composition in the solid form of tablet can be prepared using any suitable pharmaceutical carrier(s), which are commonly used in practice, such as magnesium stearate, starch, lactose, saccharose, cellulose etc.
- a composition in the solid form of capsule can be prepared using routine encapsulation procedures.
- pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatine capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatine capsule.
- Typical parenteral compositions consist of a solution or suspension of the compound of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
- the solution can be lyophilized and then reconstituted with a suitable solvent just prior to administration.
- Biological evaluation for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
- the compounds of our invention did not have COX-2 enzyme inhibition activity
- Oedema was induced by subcutaneous injection of 50 ⁇ l of 1 % carrageenan (CARR) suspension in the subplantar region of the right hind paw of male Wistar rats
- the injected carrageenan induced paw inflammation.
- the oedema i.e. the difference between the pre-and post-treatment volume (in ml) of the injected hind-paw was measured using a water displacement plethysmometer (Ugo Basile, type: 7150).
- the treated paw was immersed up to the tibio-tarsal articulation into the chamber and the volume of displaced liquid was determined as the degree of the inflammation.
- the degree of the anti-inflammatory effect of the treated group was compared to that of the control group (which obtained only vehicle).
- the test compound and the vehicle were given orally by blunt-ended needle cannula one hour before the CARR treatment.
- the volume of the treated paw was measured at 3 and 5 hours after the CARR treatment and the change in the degree of inflammation in % was calculated according to the following formula:
- Anti-inflammatory activity % 100 x [control group (ml) — treated group (ml)/control group (ml)]
- Inhibition of the oedema by Celecoxib was effective at 4 hours after treatment with an ED 30 of 23 mg/kg.
- the anti-inflammatory activity of the Celecoxib at 6 hours after the treatment was less than 30 % as compared to the control group.
- Compound of Example 5 was potent at 4 and 6 hours after treatment with an ED 30 of 5.7 mg/kg and ED 30 of 8.4 mg/kg respectively.
- the obtained results show that compound of Example 5 as compared to Celecoxib significantly inhibited paw oedema at both investigated time ⁇ points.
- Oedema inflammation was induced by subcutaneous injection of carrageenan
- the nociceptive thresholds of the inflamed hind paw after painful mechanical stimuli were measured with analgesimeter (Ugo Basile, type: 37215, Italy).
- the apparatus is suitable for the measuring of the extent and the latency of the pain reaction threshold of the sensitized paw after painful stimuli.
- the analgesics elevate the low pain reaction threshold of inflamed paw and the degree of its antinociceptive effect is expressed in reversal %.
- the withdrawal threshold was determined as the first sign (squeaking and/or struggling) of pain response.
- the pressure threshold was shown in grams.
- the average value of the hind paw withdrawal obtained with untreated right paw was regarded as the basal hind paw withdrawal (average 80- 110 grams.)
- the mechanical threshold was determined at various times to establish the magnitude and duration of the hyperalgesia.
- the maximum reduction in threshold was measured 2 - 3 h after injection (the pain threshold of the inflamed paw is 20-30 g, which was decreased by 65-80 % in comparing to the basic value).
- Acute hyperalgesia model the animals were treated with the test compounds and celecoxib (10 and 30 mg/kg p.o.) one hour after CARR treatment (100 ⁇ l 2 % suspension). Pain threshold was measured at 2 and 4 hours after the treatment.
- Chronic hyperalgesia model extended inflammation and decreased pain threshold were induced with higher dose of CARR. Pain threshold of inflamed paw was measured 24 hours after CARR treatment (150 ⁇ l, 2 % suspension) then test compound and Celecoxib (30 mg/kg p.o.) were given to the animals. Pain threshold of treated paw was measured from 30 minutes till 3 hours after treatment.
- Control groups in both models after CARR treatment were treated with vehicle p.o. at the same intervals as the test compounds.
- the analgesic effect of the compounds was expressed in the reversal (%) of the decrease of the pain threshold.
- Reversal % [mean of treated group ⁇ X h (g) - treated group ⁇ oh (g)J /
- TOh mean of the pain threshold before treatment 1 hour after CARR treatment in acute model
- Txh pain threshold after CARR treatment in the measuring times (Ih, 2h, Sh) in acute model
- Celecoxib in 30 mg/kg p.o. dose showed partial analgesic effect (24 % and 54 % reversal).
- the test compound in 30 mg/kg p.o. dose showed almost complete reversal % (90 %), so the test compound showed significantly better anti-infiammatory/analgesic effect as compared to the reference compound.
- Severity of lesions 1 : petechiae or erosion with length of 1 mm 2: erosion with length between 2 and 3 mm 3: erosion with length between 3 and 4 mm 4: erosion with length between 4 and 5 mm
- the lesion was longer than 5 mm, it was scored 4 point as many times as the total length of the lesion divisible by four and the rest of the length was evaluated according to the above scale.
- the degree of injury of mucosa was characterized by ulcer index. Ulcer index (severity of lesion x number of lesion) was calculated for every animal and the degree of injury of mucosa in the groups of tested animals was characterized by the mean of ulcer index of different groups of animals .
- Test compounds were given p.o. 40 minutes before the ethanol + HCl treatment
- test compound was given p.o. on the fifth day after the operation for seven days.
- the animals were euthanized with ether after 24 hours of the last dose and the abdomen was macroscopically examined (exravasation, accretion), the stomach was excised and the diameters of ulcers were measured.
- Table 5 The test compound was given p.o. on the fifth day after the operation for seven days.
- the animals were euthanized with ether after 24 hours of the last dose and the abdomen was macroscopically examined (exravasation, accretion), the stomach was excised and the diameters of ulcers were measured. Table 5
- Myocardial infarction was produced in male, SPRD CFY rats of 300-360 g by surgical occlusion of left anterior descending coronary artery. Briefly, the animals were anesthetized with pentobarbital (60 mg/kg i.p.) and the chest was opened, the left coronary artery was ligated for 6 minutes followed by reperfusion. Test compounds were administered i.p. in 30 and 60 mg/kg dose 30 minutes before occlusion of the coronary artery. The control group was treated with vehicle (5 % TWEEN 80 in isotonic NaCl, 2 mg/kg).
- Examples 5 and 6 was significantly (p ⁇ 0.05) higher, than that of celecoxib.
- In the inflammation induced chronic hyperalgesia model compound of Example 5 showed significant analgesic effect (p ⁇ 0.01) and its duration of action was several hours longer than that of the reference compound.
- hi comparing the gastrointestinal and cardiovascular effects compounds of Examples 5 and 6 of our invention showed significantly more favourable side-effect profile than the reference compound celecoxib.
- (+/-)-2-[4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol- l-yl)-benzenesulfonylaminooxy]-propionic acid 35 g, 74.50 mmol
- ethanol 400 ml
- sodium hydroxide solution 38.46 ml, 0.15 mol
- the product started to precipitate after 5 minutes.
- the suspension was cooled to 0-5 °C and stirred for 2 h, the product was filtered off, washed with ethanol (50 ml) and dried at 60 0 C to yield 38.39 g (96.7 %) of the title compound.
- Example 16 Disodium 2-methyl-2-[4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol-l-yl)- benzenesulfonylaminooxyj-propionic acid monohydrate
- (+/-)-2-[4-(5-p-methylphenyl-3-trifluorometliyl-pyrazol- l-yl)-benzenesulfonyl-aminooxy]-propionic acid 10 g, 21 mmol
- (-)-ephedrine 1.76 g, 10 mmol
- the mixture was stirred at room temperature for 1 day, the precipitated crystals were filtered off and washed with 91 % ethanol to yield 3.38 g (25 %) product, calculated on the basis of the starting racemic mixture.
- the so obtained crystals were recrystallized twice from 97 % ethanol to yield 2.02 g (60 %) white crystalline material.
Abstract
The present invention relates to new compounds of formula (I), (I) wherein the meaning of R1 is hydrogen atom, C1-C5 acyl group, benzoyl group or R2- COOR3 group, Y is hydrogen atom or alkali ion, R2 is C1-C4 straight or branched alkylidene group and R3 is hydrogen atom, C1-C4 alkyl group or alkali ion, and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof, which are suitable for the treatment of pain of acute and chronic inflammation origin as well as postoperative pain and dysmenorrhea. The invention also relates to the process of the synthesis of compounds of formula (I) as well as the pharmaceutical composition containing the same and the use for treatment of pain, inflammation and disorders associated with inflammation.
Description
NEW 1 , 2 -DIARYL PYRAZOLES USEFUL AS ANALGETIC AND ANTI-INFLAMMATORY AGENTS
The invention relates to new compounds of formula (I) and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, which are useful in treating pain originated from acute and chronic inflammation as well as surgical action and dysmenorrhea. Furthermore the invention relates to the synthesis of compounds of formula (I) and the pharmaceutical compositions containing them.
Description of the prior art
It is known, that selective cyclooxygenase-2 (COX-2) enzyme inhibitors have significantly more advantageous gastrointestinal side-effect profile than the traditional non-steroid anti-inflammatory agents, however, concerning the cardiovascular side- effect profile long-term use of both the traditional non-steroid anti-inflammatory agents both the coxibs can cause cardiovascular side-effects (L.A. Garcia Rodriguez, Annals of the Rheumatic Diseases 2005, 64 (Suppl. Ill) page 40). Celecoxib is the most advantageous in this respect, as its cardiovascular side-effects are less pronounced.
Celecoxib is described in the European patent EP 731795. Certain problems arose during the use of it. On the one hand celecoxib is not effective in all cases of patients therefore the research for more effective analogous drugs have started. On the other hand it is desirable to reduce the gastrointestinal side-effects. It is known from the literature that the research was focused on increasing the selective inhibition of COX-2 enzyme in order to decrease the gastrointestinal side-effects. This raises the question of cardiovascular side-effects, as according to the previous observations increasing the selectivity of COX-2 inhibition resulted in increasing cardiovascular side-effects. This was proved by the so called "VIGOR-study" of the first generation COX-2 enzyme inhibitor rofecoxib (Bombardier C, Laine L, Reicin A et al for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343(21): 1520-1528, Nov. 2000.). The possible reasons of this phenomenon are described in the study of D. Mukherjee (Mukherjee D,
Nissen SE, Topol EJ. Risk of cardiovascur events associated with selective COX-2 inhibitors. JAMA 2001;286:954-959).
Our aim was to synthesize analogous compounds, which are more effective than celecoxib and have less undesirable side-effects, on the other hand their COX-l/COX-2 selectivity remains unchanged.
Summary of the invention
Surprisingly it was found, that some of celecoxib derivatives are more effective analgetic and anti-inflammatory agents than celecoxib, furthermore they do not have in vitro COX-I and COX-2 inhibitory activity and their gastrointestinal side-effect profile is essentially more favorable, as well as they have cardioprotective activity.
The present invention relates to new compounds of formula (I),
(I)
wherein the meaning of R1 is hydrogen atom, C1-C5 acyl group, benzoyl group or R2-COOR3 group, Y is hydrogen atom or alkali ion, R2 is C1-C4 straight or branched alkylidene group and R3 is hydrogen atom, C1-C4 alkyl group or alkali ion, and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof. The invention also relates to the process of their
synthesis as well as the pharmaceutical composition containing the same and the use for treatment of pain, inflammation and disorders associated with inflammation.
Detailed description of the invention
The present invention relates to new compounds of formula (I),
(I)
wherein the meaning of R1 is hydrogen atom, C1-C5 acyl group, benzoyl group or R2-COOR3 group, Y is hydrogen atom or alkali ion, R2 is C1-C4 straight or branched alkylidene group and R3 is hydrogen atom, C1-C4 alkyl group or alkali ion, and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof.
In the meaning of Y and R2 the alkali ion is preferably sodium.
The invention also relates to solvates and hydrates of compounds of formula (I). hi those cases when compounds of formula (I) have chiral centre both stereoisomers and the racemic mixture of them are subject of the invention.
The invention also relates to the process of the synthesis of compounds of formula (I) and the chemical and pharmaceutical manufacture of pharmaceutical compositions containing the same, as well as the methods of treatment and/or prevention with these compounds, which means administering to a mammal - including human - to be treated effective amount/amounts of compounds of formula (I) of the present invention as such or as medicament.
Claisen reaction of the commercially available p-methyl-acetophenone and trifluoroacetic acid ethyl ester gave 4,4,4-trifluoro-l-(4-methylphenyl)-butane-l,3-dione in good yield. The latter was further reacted with the commercially available p- hydrazino-benzenesulfonic acid in an inert solvent in the presence of hydrochloric acid to give the new 4-(5-p-methyl-phenyl)-3-trifluoromethyl-pyrazol-l-yl)-benzenesulfonic acid of formula (III) (yield over 80%),
(HI)
which after recrystallization from an inert solvent, preferably from diisopropyl ether, can be obtained in high purity as key substance. The new intermediate of formula (III) is transformed into 4-(5-p-methylphenyl-3 -trifluoromethyl-pyrazol- 1 -yl)-benzenesulfonyl chloride of formula (II)
(H) with phosphorous pentachloride in an inert solvent, preferably in dry dichloromethane.
The obtained compound of formula (II) is reacted with hydroxylamine in an inert solvent, preferably in a mixture of water and dioxane, to furnish compound of formula (I), wherein the meaning of R1 is hydrogen atom. The reagent is formed in situ in the reaction mixture from hydroxylamine hydrochloride and sodium acetate. If compound of formula (II) is reacted with an aminooxy-alkane acid in an inert solvent, preferably in dioxane, those products of formula (I) are formed in high yield, wherein the meaning of R1 is R2-COOR3 group, wherein the meaning of R2 is C1-C4 straight or branched alkilydene group and R3 is hydrogen atom or C1-C4 alkyl group or alkali atom. If desired the obtained compounds of formula (I) can be purified by recrystallization from an inert solvent, preferably from toluene.
Those compounds of formula (I), wherein the meaning of R3 is hydrogen atom, can be transformed into alkali salts with alkali hydroxide solution, preferably with two equivalent of sodium hydroxide. The formed disodium salt can contain hydrate as solvate, preferably monohydrate. If compound of formula (II) is reacted with O-acylated hydroxylamine in an inert solvent, preferably in dioxane, those compounds of formula (I) are formed in high yield, wherein the meaning OfR1 is C1-C5 acyl group or benzoyl group.
The invention also relates to pharmaceutical compositions containing compounds of formula (I) as an active ingredient. Compounds of formula (I) can be used in treating of inflammation and disorders associated with inflammation, for example as an analgesic agent in treatment of pain and headache.
Compounds of formula (I) and/or stereoisomers and/or diastereomers can be used as such and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof as medicament, usually as a standard composition. The present invention also relates to pharmaceutical compositions containing a new compound of formula (I) and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof as well as one or more pharmaceutically acceptable adjuvant and auxiliary material. Compounds of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof may be administered by any convenient method, for example by oral, parenteral
buccal, sublingual, nasal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly. Pharmaceutical compositions containing compounds of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof when given orally can be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and chewable tablets..
Liquid formulations of compounds of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof generally consist of a suspension or solution of a compound of formula (I) in an appropriate liquid carrier(s), for example an aqueous solvent, such as water, ethanol or glycerine or a non-aqueous solvent, such as polyethylene glycol or an oil. The pharmaceutical composition can also contain a suspending agent, preservative, flavoring and coloring agents.
A composition in the solid form of tablet can be prepared using any suitable pharmaceutical carrier(s), which are commonly used in practice, such as magnesium stearate, starch, lactose, saccharose, cellulose etc.
A composition in the solid form of capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatine capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatine capsule.
Typical parenteral compositions consist of a solution or suspension of the compound of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilized and then reconstituted with a suitable solvent just prior to administration.
Biological evaluation
In vitro measurements
The compounds of our invention did not have COX-2 enzyme inhibition activity
, at 10 μM concentration — according to spectrophotometric TMPD measurements (K. Gierse, S.D. Hauser, D.P. Creely, CM. Koboldt, S.H. Rangwala, P.C. Isakson and K. Seibert, 1995: Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem. J. 305: 479-48)
In vivo assays
1. Inhibition of carrageenan induced oedema in rats
Oedema was induced by subcutaneous injection of 50 μl of 1 % carrageenan (CARR) suspension in the subplantar region of the right hind paw of male Wistar rats
(140-150 g). The injected carrageenan induced paw inflammation. The oedema, i.e. the difference between the pre-and post-treatment volume (in ml) of the injected hind-paw was measured using a water displacement plethysmometer (Ugo Basile, type: 7150).
. The treated paw was immersed up to the tibio-tarsal articulation into the chamber and the volume of displaced liquid was determined as the degree of the inflammation.
Degree of inflammation (ml) = volume after the CARR treatment (ml) — volume before the CARR treatment (ml)
The degree of the anti-inflammatory effect of the treated group (which obtained test agent) was compared to that of the control group (which obtained only vehicle). The test compound and the vehicle were given orally by blunt-ended needle cannula one hour before the CARR treatment. The volume of the treated paw was measured at 3 and 5 hours after the CARR treatment and the change in the degree of inflammation in % was calculated according to the following formula:
Anti-inflammatory activity % = 100 x [control group (ml) — treated group (ml)/control group (ml)]
Celecoxib and the compounds of the invention were measured in 1-10-30 mg/kg p.o. dose (n = 12 animal/group). Anti-inflammatory activity of the compounds was determined in % at 4 and 6 hours after p.o. treatment and ED30 was calculated.
Results:
Inhibition of the oedema by Celecoxib: was effective at 4 hours after treatment with an ED30 of 23 mg/kg. The anti-inflammatory activity of the Celecoxib at 6 hours after the treatment was less than 30 % as compared to the control group. Compound of Example 5: was potent at 4 and 6 hours after treatment with an ED30 of 5.7 mg/kg and ED30 of 8.4 mg/kg respectively. The obtained results show that compound of Example 5 as compared to Celecoxib significantly inhibited paw oedema at both investigated time ■ points.
Table 1
2. Carrageenan induced acute hyperalgesia in rats (Randall-Selitto model)
Oedema (inflammation) was induced by subcutaneous injection of carrageenan
(CARR) suspension in the subplantar region of the right hind paw of male Wistar rats, weighted 140-190 g (n = 8-12 animal/group). The nociceptive thresholds of the
inflamed hind paw after painful mechanical stimuli were measured with analgesimeter (Ugo Basile, type: 37215, Italy). The apparatus is suitable for the measuring of the extent and the latency of the pain reaction threshold of the sensitized paw after painful stimuli. The analgesics elevate the low pain reaction threshold of inflamed paw and the degree of its antinociceptive effect is expressed in reversal %.
An increasing pressure was applied to the paw and the withdrawal threshold was determined as the first sign (squeaking and/or struggling) of pain response. The pressure threshold was shown in grams. The average value of the hind paw withdrawal obtained with untreated right paw was regarded as the basal hind paw withdrawal (average 80- 110 grams.) After determining the baseline threshold the animals received carrageenan injection that produced an intense inflammation associated with hyperalgesia. The mechanical threshold was determined at various times to establish the magnitude and duration of the hyperalgesia. The maximum reduction in threshold was measured 2 - 3 h after injection (the pain threshold of the inflamed paw is 20-30 g, which was decreased by 65-80 % in comparing to the basic value).
Acute hyperalgesia model: the animals were treated with the test compounds and celecoxib (10 and 30 mg/kg p.o.) one hour after CARR treatment (100 μl 2 % suspension). Pain threshold was measured at 2 and 4 hours after the treatment. Chronic hyperalgesia model: extended inflammation and decreased pain threshold were induced with higher dose of CARR. Pain threshold of inflamed paw was measured 24 hours after CARR treatment (150 μl, 2 % suspension) then test compound and Celecoxib (30 mg/kg p.o.) were given to the animals. Pain threshold of treated paw was measured from 30 minutes till 3 hours after treatment.
Control groups in both models after CARR treatment were treated with vehicle p.o. at the same intervals as the test compounds. In both models the analgesic effect of the compounds was expressed in the reversal (%) of the decrease of the pain threshold.
Reversal % = [mean of treated group τXh (g) - treated group τoh (g)J /
[basic mean of treated group τ-ih (g) - treated group τoh (g)J
T-Ih - mean of the pain threshold of paw before CARR treatment in acute model (g)
TOh = mean of the pain threshold before treatment 1 hour after CARR treatment in acute model (g) Txh =pain threshold after CARR treatment in the measuring times (Ih, 2h, Sh) in acute model (g)
In both models (acute and chronic treatment) Celecoxib in 30 mg/kg p.o. dose showed partial analgesic effect (24 % and 54 % reversal). In the acute model the test compound in 30 mg/kg p.o. dose showed almost complete reversal % (90 %), so the test compound showed significantly better anti-infiammatory/analgesic effect as compared to the reference compound.
In the chronic model test drug showed 54 % reversal, comparable with Celecoxib analgesic effect.
Table 2 - acute model
Table 3 - chronic model
a") Gastric lesions induced by acidified alcohol
Male Wistar rats weighing 140-160 g were treated p.o. with a 1:0.02 mixture of dry ethanol and concentrated HCl (0.5 ml) in order to induce gastric lesions. One hour later the animals were euthanized with ether and the stomach excised along its greater curvature, the mucosa was examined for the presence of lesions.
Severity of lesions: 1 : petechiae or erosion with length of 1 mm 2: erosion with length between 2 and 3 mm 3: erosion with length between 3 and 4 mm 4: erosion with length between 4 and 5 mm
If the lesion was longer than 5 mm, it was scored 4 point as many times as the total length of the lesion divisible by four and the rest of the length was evaluated according to the above scale. The degree of injury of mucosa was characterized by ulcer index. Ulcer index (severity of lesion x number of lesion) was calculated for every animal and the degree of injury of mucosa in the groups of tested animals was characterized by the mean of ulcer index of different groups of animals .
Test compounds were given p.o. 40 minutes before the ethanol + HCl treatment
Table 4
Alcohol induced mucosa injury in rats (n =10)
*p<0.05
It can be seen from the above data that both celecoxib and the compound of the invention inhibited the alcohol induced mucosa injury, but the compound of the invention was significantly (p<0.05) more effective than celecoxib.
b) Acetic acid induced — chronic — gastric ulcer
In our experiments the method of Okabe et al was used. Male Wistar rats of 150- 17O g were narcotized with ether and 20 % acetic acid (0.05 ml) was subserosally injected in the glandular part of the stomach.
The test compound was given p.o. on the fifth day after the operation for seven days. The animals were euthanized with ether after 24 hours of the last dose and the abdomen was macroscopically examined (exravasation, accretion), the stomach was excised and the diameters of ulcers were measured.
Table 5
Acetic acid induced chronic gastric ulcer in rats
* p<0.05; ** p<0.01
Recovery of acetic acid induced ulcer - which is analogous to the human ulcer - was inhibited significantly by celecoxib, while compound of Example 5 did not influence it.
4. Measurement of cardioprotective effect
Effect of compound of Example 5 and celecoxib was determined in experimental myocardial ischemia-reperfusion induced injury.
Myocardial infarction was produced in male, SPRD CFY rats of 300-360 g by surgical occlusion of left anterior descending coronary artery. Briefly, the animals were anesthetized with pentobarbital (60 mg/kg i.p.) and the chest was opened, the left coronary artery was ligated for 6 minutes followed by reperfusion. Test compounds were administered i.p. in 30 and 60 mg/kg dose 30 minutes before occlusion of the coronary artery. The control group was treated with vehicle (5 % TWEEN 80 in isotonic NaCl, 2 mg/kg).
During the myocardial ischemia-reperfusion the applied pre-treatments did not influence the heart rate and the mean blood pressure of the animals.
The frequency of arrhythmia during the 6 minutes coronary artery ligation did not alter in the different groups. In those animals which were pre-treated with
compound of Example 5 (30 mg/kg) the occurrence of the serious, not mortal ventricular fibrillation, developed during reperfusion, was decreased (60 % vs. 90 % in the control group).
5. Measurement of anti-hypertensive activity in rabbit
Anti-hypertensive activity of celecoxib and compound of Example 6 (in a dose of 30 mg/kg p.o.) was compared in New Zealand white rabbits of 2.5-3.0 kg. Molsidomine was used as reference compound in 2 mg/kg dose. Compound of Example
6 showed similar anti-hypertensive activity as molsidomine (p<0.05), while celecoxib did not have such effect.
Summarising the biological results it can be seen, that according to in vivo experiments pharmacological efficacy of compounds of our invention both in extent and duration exceeds that of the reference compound celecoxib.
In CARR induced oedema test anti-inflammatory activity of compounds of
Examples 5 and 6 was significantly (p<0.05) higher, than that of celecoxib. In the inflammation induced chronic hyperalgesia model compound of Example 5 showed significant analgesic effect (p<0.01) and its duration of action was several hours longer than that of the reference compound. hi comparing the gastrointestinal and cardiovascular effects compounds of Examples 5 and 6 of our invention showed significantly more favourable side-effect profile than the reference compound celecoxib.
Examples
The invention is illustrated by the following not limiting examples.
Example 1
4,4,4-trifluoro-l-(4-methyl-phenyl)-butane-l,3-dione
Sodium metal (5.76 g, 0.25 mol) was dissolved in methanol (80 ml), then trifluoroacetic acid (22 ml, 0.168 mol) was added at room temperature, followed by dropwise addition of methyl-acetophenone (21.04 g, 0.165 mol). The obtained mixture was stirred at 80 0C for 1O h, the reaction mixture was concentrated in vacuo and the residue was dissolved in water (50 ml). The solution was acidified by addition of IN hydrochloric acid (120 ml), extracted with ethyl acetate (2 x 80 ml), dried over MgSO4, filtered and concentrated in vacuo to yield 34.60 g (95 %) of the title compound. The obtained crystalline product was used in the next step without further purification.
Example 2 4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol-l-yl)-benzenesulfonic acid
To a stirred suspension of p-hydrazino-benzenesulfonic acid (42 g, 0.223 mol) in ethanol (450 ml) 6N hydrochloric acid (74 ml, 0.446 mol) was added at room temperature, followed by addition of 4,4,4-trifluoro-l-(4-methyl-phenyl)-butane-l,3- dione (51.45 g, 0.223 mol). The obtained suspension was refluxed for 8 h, then concentrated in vacuo. The residue was dissolved in water (300 ml) and extracted with ethyl acetate (2 x 200 ml). The combined organic layers were washed with water (1 x 100 ml) and brine (1 x 100 ml), dried over MgSO4, decolorized, filtered and concentrated in vacuo. The obtained crystalline product was recrystallized from diisopropyl ether (300 ml) to yield 70.12 g (82 %) of the title compound.
Example 3 4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol-l-yl)-benzenesulfonyl chloride
To a stirred suspension of 4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol-l-yl)- benzenesulfonic acid (43 g, 0.112 mol) in dichloromethane (250 ml) phosphorous pentachloride (34.20 g, 0.168 mol) was added portion- wise at room temperature, followed by addition of N,N-dimethylformamide (10 ml). The so obtained suspension was refluxed for 8 h, then concentrated in vacuo. The residue was partitioned between ethyl acetate (150 ml) and water (150 ml) and separated. The aqueous phase was extracted with ethyl acetate (1 x 50 ml), the combined organic layers were dried over
MgSO4, filtered and concentrated. The obtained oil was crystallized from cyclohexane
(120 ml) to yield 33.40 g (74 %) of the title compound as white crystals. Mp: 97-98 0C.
Example 4 N-hydroxy-4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol-l-yl)-benzenesulfonamide
To a stirred suspension of hydroxylamine hydrochloride (2.74 g, 40 mmol) in dioxane (25 ml) sodium acetate (3.25 g, 40 mmol) in water (15 ml) was added dropwise at room temperature, followed by dropwise addition of 4-(5-p-methylphenyl-3- trifluoromethyl-pyrazol-l-yl)-benzenesulfonyl chloride (4.11 g, 10 mmol) in dioxane
(40 ml). The obtained reaction mixture was poured into water (100 ml), extracted with ethyl acetate (2 x 50 ml), the organic layers were washed with water (3 x 50 ml) and brine (1 x 50 ml), dried over MgSO4, filtered and concentrated in vacuo. The obtained oil was crystallized from 75 % aqueous ethanol (75 ml) to yield 2.94 g (75 %) of the title compound as white crystals. Mp: 203 0C.
Example 5
(R,S)-2-[4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol-l-yl)-benzensulfonylamino- oxyj-propionic acid
0.23 mol) in dioxane (100 ml) sodium acetate (18.86 g, 0.23 mmol) in water (100 ml) was added dropwise at room temperature, followed by dropwise addition of 4-(5-p- methylphenyl-3-trifluoromethyl-pyrazol-l-yl)-benzenesulfonyl chloride (38 g, 94.80 mmol) in dioxane (100 ml). The obtained reaction mixture was stirred for 5 h, then concentrated in vacuo.. The residue was dissolved in water (200 ml), extracted with ethyl acetate (2 x 100 ml), the combined organic layers were washed with water (4 x 50 ml) and brine (1 x 50 ml), dried over MgSO4, filtered and concentrated in vacuo. The obtained oil was crystallized from toluene (250 ml) to yield 37.94 g (85 %) of the title compound as white crystals. The so obtained product was dissolved in toluene (480 ml) and stirred at 0-5 °C for 1 h, the precipitated product was filtered off, washed with cold toluene and dried at room temperature to yield 36.43 g (96 %) of the title compound. Mp: 187-189 °C, HPLC: 99.9 %.
Example 6 Disodium (R,S)-2-[4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol-l-yl)- benzenesulfonyl-aminooxyj-propionic acid monohydrate
To a stirred solution of (+/-)-2-[4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol- l-yl)-benzenesulfonylaminooxy]-propionic acid (35 g, 74.50 mmol) in ethanol (400 ml) 3.9 N sodium hydroxide solution (38.46 ml, 0.15 mol) was added at room temperature.
The product started to precipitate after 5 minutes. The suspension was cooled to 0-5 °C and stirred for 2 h, the product was filtered off, washed with ethanol (50 ml) and dried at 60 0C to yield 38.39 g (96.7 %) of the title compound.
Compounds of Examples of 7-16 were synthesized according to the methods described in Examples 5 and 6.
Example 7
[4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol-l-yl)-henzenesulfonylaminooxy]~ acetic acid
Yield: 88 %. Mp: 224-225 °C.
Example 8
[4-(5-p-methylphenyl-3-trifluorotnethyl-pyrazol-l-yl)-benzenesulfonylaminooxy]~ acetic acid ethyl ester
Yield: 82 %. Mp: 143-144 °C.
Example 9
3-[4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol-l-yl)-benzenesulfonylaminooxy]- propionic acid
Yield: 92 %. Mp: 176-178 °C.
Example 10 2-[4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol-l-yl)-benzenesulfonylaminooxy]- propionic acid ethyl ester
Yield: 82 %. Mp: 137-138 °C.
Example 11 N-acetoxy-4-(5-p-methylphenyl-3~trifluoromethyl-pyrazol-l-yl)-benzenesulamide
Yield: 44 %. Mp: 138-140 °C.
Example 12
N-benzoyloxy-4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol-l-yl)- benzenesulfonamide
Yield: 40 %. Mp: 152-155 °C.
Example 13
N-pivaloyloxy-4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol-l-yl)~ benzenesulfonatnide
Yield: 72 %. Mp: 134-136 0C.
Example 14 Sodium [4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol-l-yl)-benzenesulfonyl- aminooxyj-acetic acid trihydrate
Yield: 90 %.
Example 15
Disodium 3-[4-(5-p-methylphenyl-3-tιifluoromethyl-pyrazol-l-yl)-benzenesulfonyl- aminooxyj-propionic acid monohydrate
Yield: 87 %.
Example 16 Disodium 2-methyl-2-[4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol-l-yl)- benzenesulfonylaminooxyj-propionic acid monohydrate
Yield: 53 %.
Example 17
(-)-2-[4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol-l-yl)-benzenesulfonyl- aminooxy] -propionic acid
To a stirred solution of (+/-)-2-[4-(5-p-methylphenyl-3-trifluorometliyl-pyrazol- l-yl)-benzenesulfonyl-aminooxy]-propionic acid (10 g, 21 mmol) in 97 % ethanol (50 ml) (-)-ephedrine (1.76 g, 10 mmol) was added. The mixture was stirred at room temperature for 1 day, the precipitated crystals were filtered off and washed with 91 % ethanol to yield 3.38 g (25 %) product, calculated on the basis of the starting racemic
mixture. The so obtained crystals were recrystallized twice from 97 % ethanol to yield 2.02 g (60 %) white crystalline material.
The diastereomer salt was suspended in ethyl acetate (30 ml) and 1 N hydrochloric acid (15 ml) was added. The organic layer was separated, dried over MgSO4, filtered and concentrated in vacuo. The obtained oil was crystallized from petroleum ether to yield 0.9 g (60 %) of the title compound. Mp: 158-160 0C. [α]D = - 505.3° (c = l, methanol)
Example 18
(+)-2-[4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol-l-yl)-benzenesulfonyl- aminooxy] -propionic acid
The title compound was obtained according to the method described in Example
17 using (+)-ephedrine as resolving agent and isopropanol as solvent. Yield: 0.62 g. Mp: 161-163 °C. [α]D = + 457.6° (c = 1, methanol)
Claims
1. New compounds of formula (I),
(I)
wherein the meaning of R1 is hydrogen atom, C1-C5 acyl group, benzoyl group or R2-COOR3 group, Y is hydrogen atom or alkali ion, R2 is C1-C4 straight or branched alkylidene group and R3 is hydrogen atom, C1-C4 alkyl group or alkali ion, and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof.
2. (R,S)-2-[4-(5-p-methylphenyl-3-trifluoromethyl-pyrazol-l-yl)-benzenesulfonyl- aminooxy] -propionic acid.
3. Disodium (R,S)-2-[4-(5-p-methylphenyl-3-trifluoromethyl-ρyrazol-l-yl)- benzenesulfonylaminooxy] -propionic acid monohydrate.
4. Process for the synthesis of compounds of claims 1-3 and/or geometric isomers and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof, characterized by reacting 4,4,4-trifluoro-l-(4- methylphenyl)-butane-l,3-dione with p-hydrazino-benzenesulfonic acid in an inert solvent in the presence of hydrochloric acid, then reacting the obtained compound of formula (III) with phosphorus pentachloride in an inert solvent to give compound of formula (II), which is reacted a) with hydroxylamine, or b) with a compound of formula NH2-O-R2-COOR3, wherein the meaning of R2 and R3 is the same as mentioned before, or c) with a compound of formula NH2-OCOR1, wherein the meaning of Rl is the same as mentioned before to yield compounds of formula (I).
5. Pharmaceutical composition containing a compound of claims 1-3 and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof as well as one or more pharmaceutically acceptable adjuvant and/or auxiliary material.
6. Use of a compound of claims 1-3 and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof for manufacturing a pharmaceutical composition for the treatment of inflammation and disorders associated with inflammation.
7. Method of treatment of inflammation and disorders associated with inflammation, characterized by administering to a mammal to be treated — including human — effective amount/amounts of a compound of claims 1-3 and/or stereoisomers and/or diastereomers and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06765404A EP1915347B1 (en) | 2005-07-29 | 2006-07-27 | New 1 , 2 -diaryl pyrazoles useful as analgetic and anti-inflammatory agents |
| EA200800474A EA013232B1 (en) | 2005-07-29 | 2006-07-27 | New 1,2-diaryl pyrazoles useful as analgetic and anti-inflammatory agents |
| DE602006005057T DE602006005057D1 (en) | 2005-07-29 | 2006-07-27 | A NEW 1,2-DIARYLPYRAZOLE SUITABLE AS ANALGETIC AND ANTI-INFLAMMATORY AGENTS |
| US11/989,439 US7723370B2 (en) | 2005-07-29 | 2006-07-27 | 1, 2-diaryl pyrazoles useful as analgetic and antiinflammatory agents |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0500730A HUP0500730A2 (en) | 2005-07-29 | 2005-07-29 | 1,2-diaryl-heterocyclic compounds, their preparation, pharmaceutical compositions comprising thereof and their use |
| HUP0500730 | 2005-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2007012906A1 true WO2007012906A1 (en) | 2007-02-01 |
Family
ID=89986187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/HU2006/000063 WO2007012906A1 (en) | 2005-07-29 | 2006-07-27 | New 1 , 2 -diaryl pyrazoles useful as analgetic and anti-inflammatory agents |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7723370B2 (en) |
| EP (1) | EP1915347B1 (en) |
| AT (1) | ATE421955T1 (en) |
| DE (1) | DE602006005057D1 (en) |
| EA (1) | EA013232B1 (en) |
| HU (1) | HUP0500730A2 (en) |
| WO (1) | WO2007012906A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8524504B2 (en) | 2007-08-31 | 2013-09-03 | Vivacta Limited | Sensor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995015316A1 (en) * | 1993-11-30 | 1995-06-08 | G. D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
| WO1997038986A1 (en) * | 1996-04-12 | 1997-10-23 | G.D. Searle & Co. | Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors |
| WO2004058778A1 (en) * | 2002-12-24 | 2004-07-15 | J. Uriach Y Compañia S.A. | New phosphoramide derivatives |
-
2005
- 2005-07-29 HU HU0500730A patent/HUP0500730A2/en unknown
-
2006
- 2006-07-27 WO PCT/HU2006/000063 patent/WO2007012906A1/en active Application Filing
- 2006-07-27 EA EA200800474A patent/EA013232B1/en not_active IP Right Cessation
- 2006-07-27 US US11/989,439 patent/US7723370B2/en not_active Expired - Fee Related
- 2006-07-27 DE DE602006005057T patent/DE602006005057D1/en active Active
- 2006-07-27 AT AT06765404T patent/ATE421955T1/en not_active IP Right Cessation
- 2006-07-27 EP EP06765404A patent/EP1915347B1/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995015316A1 (en) * | 1993-11-30 | 1995-06-08 | G. D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
| WO1997038986A1 (en) * | 1996-04-12 | 1997-10-23 | G.D. Searle & Co. | Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors |
| WO2004058778A1 (en) * | 2002-12-24 | 2004-07-15 | J. Uriach Y Compañia S.A. | New phosphoramide derivatives |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8524504B2 (en) | 2007-08-31 | 2013-09-03 | Vivacta Limited | Sensor |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1915347A1 (en) | 2008-04-30 |
| US7723370B2 (en) | 2010-05-25 |
| EP1915347B1 (en) | 2009-01-28 |
| EA013232B1 (en) | 2010-04-30 |
| DE602006005057D1 (en) | 2009-03-19 |
| EA200800474A1 (en) | 2008-06-30 |
| HUP0500730A2 (en) | 2007-02-28 |
| US20090036510A1 (en) | 2009-02-05 |
| HU0500730D0 (en) | 2005-10-28 |
| ATE421955T1 (en) | 2009-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2269721C (en) | 1-phenylpyrazole compounds and medicinal application thereof | |
| SU906374A3 (en) | Method for preparing n-benzylimidasole derivatives or their salts | |
| CA2463102C (en) | Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors | |
| WO2004089918A1 (en) | Heteroaromatic pentacyclic compound and medicinal use thereof | |
| CS253702B2 (en) | Process for preparing new 3-/1-imidazolylalkyl/indoles | |
| BR112012007828B1 (en) | xanthine oxidase inhibitor compounds, process for preparing the compounds, and pharmaceutical composition for xanthine oxidase inhibition | |
| JP5128959B2 (en) | New histidine derivatives | |
| IE49318B1 (en) | Imidazole derivatives | |
| NO317888B1 (en) | Arylalkanoylpyridazines, process for the preparation of the compounds, the compounds used as pharmaceuticals, pharmaceutical preparations containing them, the process for the preparation of the preparations, and the use of the compounds for the preparation of pharmaceuticals | |
| RU2196130C2 (en) | Derivatives of aminoethylphenoxyacetic acid and medicinal agents for pain relief and stone moving away relieve in cholelithiasis | |
| HU211520A9 (en) | Tetrazole derivatives and aldose reductase inhibition therewith | |
| US7723370B2 (en) | 1, 2-diaryl pyrazoles useful as analgetic and antiinflammatory agents | |
| JP6313264B2 (en) | Medicine containing cinnamic acid amide derivative | |
| JP4550353B2 (en) | Hematopoietic prostaglandin D2 synthase inhibitor | |
| JP6415985B2 (en) | Cinnamic amide derivatives | |
| US6083987A (en) | Phenylenediamine derivative, radical scavenger, brain-infarction depressant, and brain-edema depressant | |
| JP5301441B2 (en) | New histidine derivatives | |
| WO2019088057A1 (en) | Anilide derivative and medicinal use thereof | |
| JP3065506B2 (en) | Pyrazolidine derivative and radical scavenger, cerebral infarction inhibitor, cerebral edema inhibitor | |
| JP5121018B2 (en) | New histidine derivatives | |
| US6403629B2 (en) | Heterocyclic compounds for therapeutic use | |
| JP5597400B2 (en) | Medicament containing histidine derivative | |
| WO2012016510A1 (en) | Pyridazine derivatives and use thereof as medicaments for treating microrna viral infection | |
| JPH07100687B2 (en) | Novel N-hydroxyurea compounds and compositions | |
| JPS6022711B2 (en) | Trans-decahydroquinoline derivatives, their production methods, and pharmaceuticals containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2006765404 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 11989439 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 200800474 Country of ref document: EA |
|
| WWP | Wipo information: published in national office |
Ref document number: 2006765404 Country of ref document: EP |